adalimumab

Most patients who were switched from adalimumab to an interchangeable biosimilar experienced clinical success, with ...

AUGUST 18, 2025

Most patients who were switched from Humira to an interchangeable biosimilar experienced clinical success, with ...

JULY 23, 2025

There are several factors that differentiate each of the 10 biosimilars for Humira from one another.

APRIL 25, 2025

With 41 biosimilars launched for 11 branded reference products, and at least 10 more expected to enter the market ...

FEBRUARY 18, 2025

Although all 10 adalimumab biosimilars have garnered FDA approval for every indication granted to Humira, there are ...

DECEMBER 11, 2024

The introduction of Humira biosimilars to the US market in 2023 brought significant changes for providers, ...

NOVEMBER 27, 2024

The market dominance of Humira may finally be at an end, as payor formularies make dramatic shifts in favor of ...

NOVEMBER 12, 2024

Cardinal Health has released its 2024 Biosimilars Report outlining the ways in which consumers and pharmacies can ...

APRIL 17, 2024

The FDA approved Simlandi injection, the first interchangeable high-concentration, citrate-free biosimilar to ...

MARCH 4, 2024

Therapeutic strategies employing a combination of advanced therapies are starting to reveal promising outcomes in ...

JANUARY 17, 2024

SAN ANTONIO—This year will be pivotal for biosimilar adoptions, with the January launch of the first ...

MAY 22, 2023

With 2023 poised to be the year of the Humira biosimilar wave, Cardinal Health has issued a new report on market ...

FEBRUARY 28, 2023